Please login to the form below

Not currently logged in
Email:
Password:

Pfizer files suit against Merck

Pfizer is to sue Merck over the company's plan to launch a Lipitor-plus-Zetia combination pill in the US

Pfizer is to sue Merck over the company's plan to launch a Lipitor-plus-Zetia combination pill in the US.

According to the Wall Street Journal, Pfizer has filed a patent-infringement lawsuit against Merck, known as MSD outside the US and Canada, to block the drug's introduction for five years.

Cholesterol-lowering drug, Lipitor (atorvastatin), is one of Pfizer's biggest selling medicines and its patent is due to expire in the US by the end of November, 2011.

Merck is aiming to combine a generic version of Lipitor with its Zetia (ezetimibe) product, which also lowers cholesterol but by a different mechanism to Lipitor.

Both Ranbaxy Laboratories and Watson Laboratories are to launch a generic atorvastatin product on November 30, 2011, but Pfizer still holds some patents for Lipitor that do not expire for several years on which it is basing the Merck lawsuit.

13th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics